Skip to main content
Premium Trial:

Request an Annual Quote

BioFluidica Raises $6M in Series B2 Financing for Liquid Biopsy Platform, At-Home COVID-19 Test

NEW YORK ─ BioFluidica on Tuesday announced it has raised more than $6 million in initial financing from a Series B2 financing to support the commercialization of a liquid biopsy testing platform and handheld device for COVID-19 testing.

The San Diego-based company said it is targeting a total of $10 million in financing and anticipates raising the additional funding if it reaches development milestones for its handheld infectious disease detection device, which uses nanofluidics for the detection of virus particles.

BioFluidica's existing investor base led the Series B2 financing, with participation from unnamed new investors.  

"This funding will allow BioFluidica to expand the commercialization of its LiquidScan instruments and consumables for the isolation and analysis of all liquid biopsy biomarkers including cells, exosomes, and cell free nucleotides on one platform," the firm's CEO Rolf Muller said in a statement.

The financing supplements funding from the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative to advance the commercial development of its handheld device for at-home testing for COVID-19, he said. Last August, the firm announced it had received $250,000 in RADx funding.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.